Travere Therapeutics Inc. (TVTX) has unveiled new data affirming the clinical efficacy of FILSPARI (sparsentan) in treating IgA nephropathy (IgAN) and highlighting its potential applicability in focal segmental glomerulosclerosis (FSGS).
At the American Society of Nephrology (ASN) Kidney Week 2024, Travere presented findings that validated FILSPARI's effectiveness across diverse subgroups of IgAN patients studied to date, achieving significant rates of complete remission in newly diagnosed cases.
Additionally, Travere reported preliminary data indicating that FILSPARI, when combined with SGLT2 inhibitors or steroids, safely induced further reductions in proteinuria, suggesting its compatibility for combination therapy with other medications.
Moreover, the company examined a subgroup of genetic FSGS patients within the DUPLEX Study. Given the typical treatment resistance observed in genetic FSGS cases, the notable reductions in proteinuria and positive outcomes in this subgroup are promising.
Significantly, nearly 60% of patients with IgA nephropathy participating in the SPARTAN Study achieved complete remission when FILSPARI was administered as a first-line therapy.
